Europe is among the global pioneers in approval of Biosimilars. Market Size of Biosimilars market in Europe is USD XX Bn & is growing at a rate of x% y-o-y. In 2006 the EU EMA approved its first Biosimilar, Omnitrope (a biosimilar human growth hormone), since then there are close to 50 approved Biosimilars in Europe today. Countries in the region have formulated different policies for quick & safe adoption of Biosimilars in respective countries.
In this perspective, the European Commission is actively working on the impact and promotion of biosimilar uptake within the EU through its Project Group on Market Access and Uptake of Biosimilars. In call countries the pricing of medicinal products used in Ambulatory care is regulated by different regulatory bodies. This is done in such a way that price of biosimilar is some percentage less than the reference product.
Country Wise Pricing Policies
Similarly respective regulator bodies have drafted the policies for their own countries such as Russia, Ukraine, and rest of European countries. Our report provides in-depth and extensive research on regulatory policies for all European Countries.
Country Wise Reimbursements
In England the decision of reimbursement of medicinal product is take by different regulatory bodies such as biosimilar for cancer medicines is done by NHS where as for Anti-TNF it is done by clinical commission groups. In Bulgaria the reimbursement for biosimilar depends on their International Classification of Disease (ICD) code, whereas for biosimilars used in ambulatory care the reimbursement depends on market authorization.
Current List of Biosimilars Approved in Europe
The extensive list covers all Biosimilars products along with approval and MA timelines
Similarly innovators/reference medicines such as Herceptin, Avastin, Humira, Mabthera, Avonex, etc. will be losing patents in Europe sooner, therefore, the markets are going to see new blockbuster biosimilars in very near future.
Competitive profiles of various companies are included in this report. Those companies are Hospira, Sandoz, TEVA, Accord, Ratiopharm, Eli Lilly, Celltrion, Accord Healthcare, etc.
To get a copy of Table of Contents (ToC), Report Blue Print or Sample Copy please Click HERE
To get a copy of List of Deliverables please share your requirements HERE
We offer customized reports as per our customers requirements. This covers a 360 degree deliverable scope study such as:
This section covers very brief quick reports as a scale down version of original Market Research report. You may be any of the following:
Please don’t worry and write to us HERE
For any other discussion such as related to various reports, future business requirements, feasibility discussion, etc. Or for talk to our sales team executive please feel free to reach out to us HERE